Biopolym. Cell. 2004; 20(6):472-478.
http://dx.doi.org/10.7124/bc.0006CC
Огляди
Нестероїдні протизапальні препарати: можливі механізми антиоксидантної дії
1Литвинова Н. В., 1Курапова Т. М.
  1. Інститут фармакології та токсикології АМН України
    вул. Ежена Потьє, 14, Київ, Україна, 03057

Abstract

Нестероїдні протизапальні препарати (НПЗП) широко засто­совують у медицині завдяки наявності у них протизапальних, антипіретичних та анальгезуючих властивостей. Пригнічення поліферментного комплексу простагландин синтази є основ­ ним механізмом, шр визначає протизапальний та, певною мірою, антиоксидантний ефекти НПЗП. Обговорюються ідеякі інші можливі механізми антиоксидантної дії НПЗП, а саме: здатність підвищувати активність антиоксидантних ферментів, таких як супероксиддисмутаза, глутатіон-пероксидаза, глутатіон-S-трансфераза; впливати на транспортні властивості сироваткового альбуміну; стабілізувати струк­туру біомембран; запобігати дифузії кисню, каталізаторів та активаторів перекисного окислення ліпідів у гідрофобні ділян­ки мембран. Вважають, шр механізми реалізації антиоксидан­ тної дії НПЗП є індивідуальними для кожної речовини та залежать, головним чином, від її хімічної будови.
Повний текст: (PDF, російською)

References

[1] Vasil'yev YuN, Nazarov GF. Inflammation and anti-inflammatory agents. Moscow, Medicine, 1980; 39 p.
[2] Dyadyk OI, Laryna TF, Halayeva YaYu. Nonsteroidal anti-inflammatory drugs. Problems of therapy. Liky. 1998; 3:26-30.
[3] Klebanov BM. Pharmacological regulation of inflammation : current problems and prospects. Eksp Klin Farmakol. 1992; 55 (4):4-8.
[4] Mashkovskiy MD. Medicines. Kharkov: Torsing, 1998; 2, 592 p.
[5] Sigidin YaA, Shvarts GYa, Arzamastsev AP, Liberman SS. Drug therapy of inflammation (experimental and clinical pharmacology of anti-inflammatory drugs). Moscow, Medicine, 1988; 240 p.
[6] Trinus FP, Bukhtiarova TA. Pharmacology non-narcotic analgesics. Farmakologya i toksikologiya. 1991; 54(6):57-60.
[7] Trinus FP, Klebanov BM, Gandzha IM, Seyfulla RD. Pharmacological regulation of inflammation. Kiev, Zdorov'ya, 1987; 144 p.
[8] Cronin ME, Wortmann RL. Nonsteroidal antiinflammatory drugs (NSAIDs). Common chemical and clinical characteristics. Int J Dermatol. 1984;23(6):411-3.
[9] Nasonov EL, Lebedeva OV. Non-steroidal anti-inflammatory drugs: mechanism of action and clinical use in rheumatology. Provizor. 1998; 3:43-4.
[10] Hubs'kyy YuI. Biological Chemistry. Kyiv, Ternopil', Ukrmedknyha, 2000; 508 p.
[11] Vidal Dictionary. Drugs in Russia. Moscow, AstraFarmService, 1997; 1504 p.
[12] Stroyev YeA. Biological Chemistry. Moscow, Vysh. Shkola, 1986; 479 p.
[13] Trinus FP, Mokhort NA, Klebanov BM. NSAIDs. Kiev, Zdorov'ya, 1975; 239 p.
[14] Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med. 1991;324(24):1716-25.
[15] Veremeyenko KN. Proteolytic enzymes and their inhibitors in medicine. Animal and human biochemistry (Chemistry and biochemistry of enzymes). 1981; 5:28-40.
[16] Veremeyenko KN, Goloborod'ko OP, Kizim AI. Proteolysis in normal and pathological conditions. Kiev, Zdorov'ya, 1988; 198 p.
[17] Pogorelaya NF. Research prekallekrein kallekreinovoy-plasma system: Dis. ... Cand. biol. Sciences. Kiev, 1984; 167 p.
[18] Iudaev NA, Pankov IuA, Babichev VN, Fedotov VP, Shvachkin IuP. Biologically active fragments of protein hormones. Vopr Med Khim. 1984;30(3):8-15.
[19] Lankin BZ. Enzymatic regulation of metabolism and lipoperoksidnoy structural and functional reorganization of biological membranes in normal and pathological states: Author. dis. ... Dr. biol. Sciences. M., 1985. 49 p.
[20] Varfolomeyev SD, Mevkh AT. Prostaglandins - molecular Bioregulators. Moscow, Izd. University Press, 1985; 308 p.
[21] Prostaglandin I. Ed. IS Azhgikhin. Moscow, Medicine, 1978; 416 p.
[22] Morita I, Murota SI. Prostaglandin-synthesizing system in rat liver. Eur J Biochem. 1978;90(3):441-9. Eur J Biochem. 1978;90(3):441-9.
[23] Ogino N, Ohki S, Yamamoto S, Hayaishi O. Prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. Inactivation and activation by heme and other metalloporphyrins. J Biol Chem. 1978;253(14):5061-8.
[24] Prostaglandins: Biology and chemistry of prostaglandin's and related eicosanoids, Ed P. B. Curtos-Edinburg etc 1988; p. 698.
[25] Romaniyev EF, Zhulanova ZI, Pryanishnikova YeN, Nikandrova TI, Agayeva VS. Prostaglandins and interphase cell death. Radiobiologiia. 1986;26(5):579-90..
[26] Metelitsa DI. Oxygen activation enzyme systems. Moscow, Nauka, 1982; 256 p.
[27] Marnett LJ, Reed GA. Peroxidatic oxidation of benzo[a]pyrene and prostaglandin biosynthesis. Biochemistry. 1979;18(14):2923-9.
[28] Mead J.F. Free radical mechanisms in lipid peroxidation and prostaglandin's. Free radical in molecular biology, aging and disease, New York; 1984 pp. 53-66.
[29] Basha A, Brooks DW, Stewart AO, Bell RL, Carter GW. Second generation leukotriene biosynthesis inhibitors. Pure and Applied Chemistry. 1994; 66(10-11):2197–2200
[30] Degen GH. Prostaglandin-H synthase containing cell lines as tools for studying metabolism and toxicity of xenobiotics. Toxicology. 1993;82(1-3):243-56.
[31] Hsi LC, Hoganson CW, Babcock GT, Smith WL. Characterization of a tyrosyl radical in prostaglandin endoperoxide synthase-2. Biochem Biophys Res Commun. 1994;202(3):1592-8.
[32] Baraboy VA, Sutkovoy DA. Oxidation-antioxidant homeostasis in normal and pathological conditions. Ed. YuYa Zozylia. Kiev, Chernobylinterinform, 1997; 340 p.
[33] Kukhar' VP, Luyk AI, Mogilevich SYe. Chemistry bioregulatory processes. Kiev: Naukova Dumka, 1991. 368 p.
[34] Panosyan AG, Grigoryan GKh, Arakelyan ON, Mkhitaryan LS. Prostaglandins blood of animals after acute exposure. Med Radiol (Mosk). 1992; 3-4:48-51.
[35] Spasov AA, Ostrovskiy OV, Ivakhnenko IV, Kosolapoye VA, Anisimova VA. The effect of compounds with antioxidant properties on thrombocyte functional activity. Eksp Klin Farmakol. 1999;62(1):38-40.
[36] Weidemann MJ, Peskar BA, Wrogemann K, Rietschel ET, Staudinger H, Fischer H. Prostaglandin and thromboxane synthesis in a pure macrophage population and the inhibition, by E-type prostaglandins, of chemiluminescence. FEBS Lett. 1978;89(1):136-40.
[37] Vladimirov IuA, Shestnev MP, Azimbaev TK. Evaluation of the antioxidant and antiradical activities of substances and biological objects using iron-initiated chemiluminescence. Biofizika. 1992;37(6):1041-7.
[38] Kovalevskii EI, Klebanov GI, Teselkin IuO, Babenkova IV, Guseva MR. Antioxidant activity of pharmaceutical preparations used for treating eye diseases. Vestn Oftalmol. 1987;103(4):48-51.
[39] Sidorik YeP, Bagley YeA, Danko MI. Biochemiluminescence with malignancy. Kiev, Naukova Dumka, 1989. 220 p.
[40] Gubskiy YuI, Trinus FP, Bukhtiarova TA, Goryushko AG, Danilenko VF, Sachenko LG. Structural modification of membranes of rat blood mononuclear cells in experimental arthritis and pharmacotherapy NSAIDs. Zhurnal Akademii meditsinskikh nauk Ukrainy. 1999; 5(1):110-20.
[41] Gubskiy YuL, Horyushko HH, Kurapova TM, Vistunova IYe, Danylenko VP. Antioxidant and antiradical activity amison, acetylsalicylic acid and ortofen. Liky. 1999; 3-4:55-9.
[42] Karpova OI. Amizon - new domestic non-narcotic analgesic. Probl. meditsiny. 1998; 3:38-9.
[43] Dinis TC, Maderia VM, Almeida LM. Action of phenolic derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. Arch Biochem Biophys. 1994;315(1):161-9.
[44] Prasad K, Laxdal VA. Hydroxyl radical-scavenging property of indomethacin. Mol Cell Biochem. 1994;136(2):139-44.
[45] Kukoba TV, Seredenko MM. Lipid peroxidation and antioxidant system in circulatory-hemic hypoxia and its correction indomethacin. Liky. 1998; 3:39-42.
[46] Pennington SN, Smith CP. Indomethacin stimulation of lipid peroxidation and chemiluminescense in rat liver microsomes. Lipids. 1978;13(10):636-43.
[47] Harding JJ, Egerton M, Harding RS. Protection against cataract by aspirin, paracetamol and ibuprofen. Acta Ophthalmol (Copenh). 1989;67(5):518-24.
[48] Prescott LF. Paracetamol: past, present, and future. Am J Ther. 2000;7(2):143-7.
[49] Shyadehi AZ, Harding JJ. Investigations of ibuprofen and paracetamol binding to lens proteins to explore their protective role against cataract. Biochem Pharmacol. 1991;42(11):2077-84.
[50] Saso L, Silvestrini B. Antidenaturant drugs for cataract and other condensation diseases. Med Hypotheses. 2001;56(1):114-20.
[51] Saso L, Valentini G, Casini ML, Grippa E, Gatto MT, Leone MG, Silvestrini B. Inhibition of heat-induced denaturation of albumin by nonsteroidal antiinflammatory drugs (NSAIDs): pharmacological implications. Arch Pharm Res. 2001;24(2):150-8.
[52] Gubskii IuI, Goriushko AG, Litvinova NV, Pirmak RG, Kruskaia NM, Shnurko EV, Sachenko LG. Antioxidant properties and membranotropic effect of certain derivatives of 1,4-dihydropyridine. Ukr Biokhim Zh. 1999;71(4):35-9.
[53] Gubskii IuI, Goriushko AG, Shnurko EV, Sachenko LG. Interaction of antioxidants with differing chemical structure with a phospholipid bilayer.Ukr Biokhim Zh. 1994;66(2):53-8.
[54] Gubskii IuI, Litvinova NV, Shnurko-Tabakova EV. Antioxidant and antiradical activity of various classes of antioxidants. Ukr Biokhim Zh. 1994;66(4):114-7.
[55] Shi X, Ding M, Dong Z, Chen F, Ye J, Wang S, Leonard SS, Castranova V, Vallyathan V. Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Mol Cell Biochem. 1999;199(1-2):93-102.
[56] Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J. 1984;219(1):1-14.
[57] Nasyrov KhM. Antioxidant properties of anti-inflammatory agents. Farmakol Toksikol. 1987;50(6):113-6.
[58] Simchowitz L, Mehta J, Spilberg I. Chemotactic factor-induced generation of superoxide radicals by human neutrophils: effect of metabolic inhibitors and antiinflammatory drugs. Arthritis Rheum. 1979;22(7):755-63.
[59] Orhan H, Sahin G. In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes. Exp Toxicol Pathol. 2001;53(2-3):133-40.
[60] Podpletnya OA. Impact of non-narcotic analgesics on some indices of lipid peroxidation in brain structures of rats. Odes'kyy medychnyy zhurn. 1999; 51(1):13-5.
[61] Konukoglu D, Tasci I, Cetinkale O. Effects of cyclosporin A and ibuprofen on liver ischemia-reperfusion injury in the rat. Clin Chim Acta. 1998;275(1):1-8.
[62] Takayama F, Egashira T, Yamanaka Y. Effect of diclofenac, a non-steroidal anti-inflammatory drug, on lipid peroxidation caused by ischemia-reperfusion in rat liver. Jpn J Pharmacol. 1994;64(2):71-8.
[63] Bukhtiarova TA. Amizon - a new non-opioid analgesic with anti-inflammatory, antipyretic and erferonogenie properties. Liky. 1997; 3:69-71 .
[64] Trynus FY, Horyushko HH, Bukhtiarova TA, Voloshenyuk TH. Effect of NSAIDs on the structural and functional organization of the membranes of peripheral blood mononuclear cells in adjuvant arthritis: Abstracts I Congress pharmacologists Ukraine (Poltava, September 27-29, 1995). Kyiv, 1995; 168-169.
[65] Gubskii YuI, Horyushko HH, Prymak RH, Litvinova NV, Kurs'ka YM, Vistunova IE, Kurapova TM, Sachenko LH. Study of structural functional state of the membrane of the endoplasmic reticulum of rat liver by terms poisoning tetrachloroethene and pharmacological correction of acetylsalicylic acid. Medychna khimiya. 2000; 2(1):12-6.
[66] Gubskii YuI, Horyushko HH, Levitskiy YeL, Kurapova TM, Marchenko AN, Danilenko VF, Ovrutskiy VV, Pasechnik MF. Antioxidative derivatives pyridinecarboxylic acids on serum rats with carbon tetrachloride intoxication. Sovremennyye problemy toksikologii. 2001; 2:17-20.
[67] Gubskii YuY, Levyts'kyy YeL, Horyushko HH, Marchenko OM, Danylenko VP, Ovruts'kyy VM, Kurapova TM, Velychko AM, Babenko LP. Interaction of new derivatives pirydynkarbonovyh acid fractions isolated from the nuclear chromatin of intact liver cells and rat poison tetrachloroethene. Sovremennyye problemy toksikologii. 2002; 2:26-32.
[68] Hubskiyi IuI, Horiushko AH, Vistunova IIe, Marchenko OM, Kurapova TM, Danylenko VP, Sachenko LH. Effect of amizon on structural modifications of liver nuclear chromatin from rats, intoxicated with tetrachloromethane. Ukr Biokhim Zh. 1999;71(6):43-6.
[69] Kurapova TN. Amizon - an inhibitor of peroxidation reactions in the microsomal fraction of rat liver. Odes'kyy medychnyy zh. 1990; 53(3):13-6.
[70] Frolov VM, Ter'oshyn VO, Bukhtiarova TA, Danylenko VP, Klokol DYe, Khomenko VS. Effectiveness of the new Ukrainian drug "Amizon" in chronic toxic hepatitis and its impact on the performance of lipid peroxidation and antioxidant defense system. Liky. 2000; 5:3-6.
[71] Kurapova TI, Gudzenko AV. Effect " Amizona " substance and PV-4 on the activity of serum enzymes in rats intoxicated with carbon tetrachloride. IV Ukr. conf. IV Ukrainian conference of young scientists dedicated to the memory of academician Vladimir Veniaminovich Frolkis (Kyiv, January 28, 2002). Kyiv, 2002; 132-3.
[72] Lankin VZ, Roginskii VA, Tikhaze AK, Barsukova TK, Ivanova MV, Samuilov IaD, Kukharchuk VV. Antiradical and antioxidant properties of probucol and its structural analogs during oxidation of unsaturated phospholipids in native and artificial membranes. Dokl Akad Nauk. 1996;351(4):554-7.
[73] Cai Y, Appelkvist EL, DePierre JW. Hepatic oxidative stress and related defenses during treatment of mice with acetylsalicylic acid and other peroxisome proliferators. J Biochem Toxicol. 1995;10(2):87-94.
[74] Luyk AI, Luk'yanchuk VD. Serum albumin and biotransport poisons. Moscow, Medicine, 1984; 224 p.
[75] Chekman IS. Biochemical Pharmacology. Kiev, Zdorov'ye, 1991. 200 p.
[76] Fehske KJ, Muller WE, Wollert U. The location of drug binding sites in human serum albumin. Biochem Pharmacol. 1981;30(7):687-92.
[77] Levyts'kyy YeL, Horyushko HH, Prymak RH, Marchenko OM, Vistunova IE. Henomozahysnoyi mechanism of action of aspirin if rats are poisoned tetrachloroethene. Liky. 1998; 3:53-7.
[78] Kostiuk VA, Potapovich AI, Soroka NF. Antioxidative activity of antiarthritic preparations. Vopr Med Khim. 1990;36(3):37-9.
[79] Morugova TV, Lazareva DN. The effect of drugs on free-radical oxidation. Eksp Klin Farmakol. 2000;63(1):71-5.
[80] Tsujimoto Y, Saitoh K, Kashima M, Shiozawa A, Kozuka M, Hashizume H, Kimura K, Yamazaki M, Fujii A. Effect of nonsteroidal anti-inflammatory drugs on lipid peroxidation by hydroxyl radical. Gen Pharmacol. 1998;31(3):405-8.
[81] Lipsky LP, Abramson SB, Crofford L, Dubois RN, Simon LS, van de Putte LB. The classification of cyclooxygenase inhibitors. J Rheumatol. 1998;25(12):2298-303.
[82] Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum. 2003;48(1):12-20.